Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor

BACKGROUND & AIMS: A significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yang, Hao, He, Guo, Luwei, Yang, Ge, Zhang, Xiefu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354647/
https://www.ncbi.nlm.nih.gov/pubmed/28052037
http://dx.doi.org/10.18632/oncotarget.14359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354647/
https://www.ncbi.nlm.nih.gov/pubmed/28052037
http://dx.doi.org/10.18632/oncotarget.14359

Ejemplares similares